Table 1.
Afatinib (n = 41) | |
---|---|
Age (years), median (range) | 54 (30–86) |
ECOG performance status, n (%) | |
0 | 24 (59) |
1 | 14 (34) |
2 | 3 (7) |
Progesterone receptor-positive, n (%) | 12 (29) |
Estrogen receptor-positive, n (%) | 20 (49) |
Duration of prior trastuzumab (months), n (%) | |
≤6 | 3 (7.3) |
6–12 | 10 (24.4) |
12–36 | 20 (48.8) |
>36 | 8 (19.5) |
Best response to trastuzumab, n (%) | |
Complete response | 2 (4.9) |
Partial response | 13 (31.7) |
Stable disease | 13 (31.7) |
Progressive disease | 9 (22.0) |
Unknown | 2 (4.9) |
Not applicable | 2 (4.9) |
Number of prior chemotherapies | |
Median | 3 |
Range | 0–15 |
Other prior therapies; n (%) | |
Hormone | 24 (59) |
Radiotherapy | 32 (78) |
Surgery | 38 (93) |
Immunotherapy | 23 (56) |
ECOG Eastern Cooperative Oncology Group